Li, Zhu
Chen, Junyi
Kong, Ziren
Shi, Yixin
Xu, Mengxin
Mu, Bo-Shuai
Li, Nan
Ma, Wenbin
Yang, Zhi
Wang, Yu
Liu, Zhibo http://orcid.org/0000-0002-5587-4165
Funding for this research was provided by:
Natural Science Foundation of Beijing Municipality (Z200018, 7232351)
National Natural Science Foundation of China (22225603)
Ministry of Science and Technology of the People’s Republic of China (2021YFA1601400)
Changping Laboratory (Changping Laboratory)
Science Foundation of Peking University Cancer Hospital (PY202309)
Special Research Fund for Central Universities, and Peking Union Medical College (3332022024)
National High Level Hospital Clinical Research Funding (2022-PUMCH-A-019)
Article History
Received: 13 September 2023
Accepted: 1 January 2024
First Online: 9 January 2024
Change Date: 22 March 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00259-024-06678-x
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki, approved by the Institutional Review Board of the Peking University Cancer Hospital (ID 2021KT38), and registered at clinicaltrials.gov (NCT05987098). Written informed consent was obtained from all participants.
: Junyi Chen, Mengxin Xu, and Zhibo Liu are consultants of Boomray Pharmaceuticals (Beijing) Co., Ltd. No other potential conflicts of interest relevant to this article exist.